Influence of Ivabradine combined with Levosimendan on ventricular remodeling in senile patients with chronic heart failure
LU Yaohua1 SHEN Weihua2▲
1.Department of Pharmacy, Affiliated Sixth People′s Hospital of Shanghai Jiaotong University, Shanghai 200233, China;
2.Department of Pharmacy, Jinshan District Central Hospital of Shanghai, Shanghai 201599, China
Abstract：Objective To observe the benefit of Iavbredine combined with Levosimendan in the treatment of senile patients with chronic heart failure (CHF) and to analyze the effect of drugs on ventricular remodeling in patients. Methods From July 2018 to July 2019, 70 cases with senile patients with CHF who treated in Affiliated Sixth People′s Hospital of Shanghai Jiaotong University were selected as the study subjects. They were divided into the observation group and the control group according to the random table number method, with 35 cases in each group. Two groups were given routine treatment, and the control group was treated with Levosimendan on this basis, and the observation group was treated with Ivabradine on this basis of the control group, with two weeks of continuous treatment. The myocardial fibrosis indexes (Ⅰ collagen crosslinked carboxy terminal peptide [ⅠCTP], hyaluronic acid [HA], connective tissue growth factor [CTGF], laminin [LN], procollagen Ⅲ N-terminal propeptide [PⅢNP]) and ventricular remodeling indexes (left ventricular mass index [LVMI], left ventricular fraction shortening [LVFS], inter-ventricular septum end-stolic thickness [IVSS], left ventricular posterior wall thickness [LVPWT]) of the patients were detected before treatment and after treatment for two weeks. The adverse reactions during the treatment were recorded. Results There were no statistically differences in ⅠCTP, HA, CTGF, LN, PⅢNP, LVMI, LVFS, IVSS and LVPWT between the two groups before treatment (P > 0.05). The levels of ⅠCTP, HA, CTGF, LN, PⅢNP, LVMI, IVSS and LVPWT after treatment for two weeks were lower than those before treatment, and the observation group was lower than the control group; the level of LVFS was higher than that before treatment, and the observation group was higher than the control group, and the differences were statistically significant (all P < 0.05). There were no statisticaliy differences in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Ivabradine combined with Levosimendan in treatment of senile patients with CHF can delay the the further development of myocardial fibrosis and ventricular remodeling, and the drug combination will not increase the adverse reactions, which have good safety and high application value.
[1] Ramirez J，Orini M，Minchole A，et al. T-Wave Morphology Restitution Predicts Sudden Cardiac Death in Patients With Chronic Heart Failure [J]. J Am Heart Assoc，2017， 6（5）：e005310.
[2] Zeng D，Chen H，Jiang CL，et al. Usefulness of three-dimensional spherical index to assess different types of left ventricular remodeling：A meta-analysis [J]. Medicine（Baltimore），2017，96（36）：e7968.
[3] 陈艳梅，武云涛，田国祥，等.伊伐布雷定对高龄老年慢性心力衰竭患者心率及心功能的影响[J].医学综述，2019，25（23）：4767-4770，4775.
[4] 曾光豪，金杰，彭沪.不同剂量左西孟旦对慢性心力衰竭患者影响的对比研究[J].实用心脑肺血管病杂志，2017， 25（7）：62-65.
[5] 颜素岚，郑昭芬，练宇，等.心力衰竭患者心功能分级、血清N末端脑钠肽前体与甲状腺激素水平的相关性研究[J].中华生物医学工程杂志，2017，23（1）：19-23.
[6] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志，2007，35（12）：1076-1095.
[7] 常娟，张伟，王玉霄.基于时机理论的护理干预对老年慢性心力衰竭患者照顾者负担生命质量及心理状态的影响[J].山西医药杂志，2017，46（18）：2271-2275.
[8] Amat-Santos IJ，Varela-Falcon LH，Abraham WT. Current and Future Percutaneous Strategies for the Treatment of Acute and Chronic Heart Failure [J]. Rev Esp Cardiol，2017，70（5）：382-390.
[9] 孟晓京，项宁，刘亚军.载脂蛋白E、热休克蛋白27在慢性心力衰竭患者中表达及临床意义[J].心脑血管病防治，2019，19（1）：57-60.
[10] Sato M，Sakata Y，Oikawa T，et al. Prognosis and Prognostic Factors of Elderly Patients With Chronic Heart Failure—A Report From the CHART-2 Study [J]. J Card Fail，2017，23（10）：S80.
[11] Yang W，Zhang F，Tang H，et al. Summed thickening score by myocardial perfusion imaging：A risk factor of left ventricular remodeling in patients with myocardial infarction [J]. J Nucl Cardiol，2018，25（3）：742-753.
[12] 俞瑞群，王丹，吴晓蓉，等.左西孟旦治疗老年慢性心力衰竭急性加重患者的临床疗效[J].实用心脑肺血管病杂志，2018，26（5）：88-90.
[13] 毕健成，刘群英.新活素联合左西孟旦治疗对慢性心衰急性发展患者尿量及BUN水平的影响研究[J].中外医学研究，2020，18（18）：135-137.
[14] 李静，吕国芬，刘俊法.不同剂量左西孟旦治疗急性充血性心力衰竭伴肾功能不全的临床对照研究[J].临床和实验医学杂志，2019，18（5）：512-515.
[15] 张铭杰，王丽宏，孙志军.左西孟旦对高龄患者左心衰的疗效及安全性观察[J].解放军医学院学报，2017，38（11）：1022-1025.
[16] Cescau A，Aelst LNL，Baudet M，et al. High body mass index is a predictor of left ventricular reverse remodelling in heart failure with reduced ejection fraction：BMI and LV remodelling [J]. ESC Heart Fail，2017，4（4）：686-689.
[17] Avula HR，Leong TK，Lee KK，et al. Long-Term Outcomes of Adults With Heart Failure by Left Ventricular Systolic Function Status [J]. Am J Cardiol，2018，122（6）：1008-1016.
[18] Hu DY，Huang DJ，Yuan ZY，et al. Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure：subgroup analysis of Chinese patients in the SHIFT study [J]. Zhonghua Xin Xue Guan Bing Za Zhi，2017，45（3）：190-197.
[19] 杨茂，贾静，王岩，等.伊伐布雷定对糖尿病合并慢性心力衰竭患者心功能及心率变异性的影响[J].疑难病杂志，2019，18（4）：325-328.
[20] 李秋霞，慕春言.伊伐布雷定联合左西孟旦治疗慢性心力衰竭的临床研究[J].现代药物与临床，2019，34（6）：1630-1634.
[21] 任丽，梁秀利，梁萧，等.左西孟旦治疗右心衰竭伴肺高血压的疗效和安全性研究[J].中国医院用药评价与分析，2019，19（5）：555-559.
[22] 易日霞，李朋，李睿，等.美托洛尔与伊伐布雷定联合控制心率对急诊PCI患者短期预后的影响[J].中国医药导报，2018，15（5）：54-57.
[23] 胡圣大，曹明强，李晓波，等.伊伐布雷定治疗急性心肌梗死合并心力衰竭的疗效[J].江苏医药，2018，44（12）：1428-1431.
2020, Vol. 17 
京公网安备 11010502046598号